resistanceBio has built the first cancer treatment resistance system to predict how multiple cancer types will respond to approved or novel treatments. The ResCu platform aims only to advance therapies that have the potential to be superior to the standard of care and significantly extend patients’ lives. ResCu addresses the root cause of treatment failure, which is treatment resistance.
Founded in September 2021

Is this your company?

If you're responsible for hiring at this company, make sure your company and job information are always up to date to attract top talent from the NFX Guild network.

Inaccurate data? Flag it here.
Open jobs at resistanceBio